Clinical Trial

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA’s Potential Market

Study to evaluate clinical effectiveness of low-dose oral interferons in treating chronic gingivostomatitis in cats, building upon VELDONA's history in…

1 month ago

Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform

OTA capability enhances introduction of new assays from rapidly expanding menuANN ARBOR, MI / ACCESSWIRE / May 15, 2024 /…

1 month ago

NanoViricides Has Filed its Quarterly Report

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15,…

1 month ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

1 month ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR…

1 month ago

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 month ago

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…

1 month ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived…

1 month ago

Tenon Medical Reports First Quarter 2024 Financial Results

~ Revenue Increased 66% Year-Over-Year ~~ Surgical Procedures Increased 42% Year-Over-Year ~~ Gross Margin Stabilized at 65% Sequentially ~~ Catamaran®…

1 month ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic…

1 month ago